BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8788134)

  • 1. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.
    Poon GK; Mistry P; Raynaud FI; Harrap KR; Murrer BA; Barnard CF
    J Pharm Biomed Anal; 1995 Nov; 13(12):1493-8. PubMed ID: 8788134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
    Poon GK; Raynaud FI; Mistry P; Odell DE; Kelland LR; Harrap KR; Barnard CF; Murrer BA
    J Chromatogr A; 1995 Sep; 712(1):61-6. PubMed ID: 8556156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
    Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
    Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI; Odell DE; Kelland LR
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
    Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
    J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A validated liquid chromatography/tandem mass spectrometry assay for cis-amminedichloro(2-methylpyridine)platinum(II) in human plasma ultrafiltrate.
    Oe T; Tian Y; O'Dwyer PJ; Roberts DW; Malone MD; Bailey CJ; Blair IA
    Anal Chem; 2002 Feb; 74(3):591-9. PubMed ID: 11838680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid biotransformation of satraplatin by human red blood cells in vitro.
    Carr JL; Tingle MD; McKeage MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV), an orally active anticancer drug.
    Neidle S; Snook CF; Murrer BA; Barnard CF
    Acta Crystallogr C; 1995 May; 51 ( Pt 5)():822-4. PubMed ID: 7779322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.
    Zhang W; Seymour L; Chen EX
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):277-82. PubMed ID: 19026601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216.
    Vouillamoz-Lorenz S; Bauer J; Lejeune F; Decosterd LA
    J Pharm Biomed Anal; 2001 Jun; 25(3-4):465-75. PubMed ID: 11377026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of platinum-based drugs with native biologically relevant proteins.
    Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
    Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.